You are now visiting tipharma.com.
On 1 January, 2016, TI Pharma and CTMM merged
to form a new organization called Lygature.
Please note that information on the tipharma.com site has not
been updated since, and is retained as an archive.
For up-to-date information, please visit lygature.org.
In drug development, pharmaceutical companies and academic hospitals develop large databases with information on what a medicine does with the human body, and what the human body does with the medicine. Based on this information "pharmacokinetic" and "pharmacodynamic" (PK/PD) models are created that can help, for example, to design clinical studies for developing new medicines and for defining for example the right dosage for medicines.
By coupling databases from various partners, better statistics can be obtained. This results in improved clinical protocols for the elderly and for children (for which, by nature, less data points are available) and finding optimal dosage forms. A concrete result from the models developed within this TI Pharma consortium is a new dosage regime for the use of morphine in children.
The partners of this platform share their data, enabling them to generate powerful mathematical models to predict among others a safe morphine dosing regimen for newborns.
“Running public-private partnerships is a profession by itself. TI Pharma is an excellent example of how you can do this in an effective way.”
Director/Secretary of the Medicines Evaluation Board